Vyvanse has been approved by the Food and Drug Administration to treat Attention Deficit Hyperactivity Disorder (ADHD) for children six years old to twelve years old. This medication has not been tested in children under the age of six and should not be given to children five and under.
Vyvanse is a short acting medication Normally, the first dose of Vyvanse is taken first thing in the morning. Additional doses can...Read more
The effects of hormones and neutransmitters as they relate to mania and depression are extremely complex and far beyond the scope of a... Read more »
Yesterday the U.S. Food and Drug Administration announced that it is asking manufacturers of prescription combination products that contain... Read more »
The U.S. Food and Drug Administration (FDA) approved NEXIUM® delayed release capsules in children ages 12 to 17 for the short-term treatment of... Read more »